康护乐抗癌新特药：恶液质药物ADLUMIZ(Anamorelin)于日本上市

Cachexia is also called cachexia. Symptoms include extreme weight loss, anemia, weakness, complete bed rest, and systemic failure. It is mostly caused by cancer and other serious chronic diseases. Among them, cachexia associated with tumors is the most common, called cancer cachexia (CC). CC is a secondary reaction characterized by systemic metabolic disorder mainly caused by tumor cell products and cytokines released by the body. Patients often cannot receive further active treatment due to the occurrence of CC, thus missing the opportunity to extend survival and improve quality of life. 50% to 80% of patients with malignant tumors will develop cachexia before death, and the probability of death directly due to CC is as high as 20%. CC has serious adverse effects on the quality of life and prognosis of cancer patients. Regarding the drug intervention treatment of CC, multiple clinical trials have been carried out to explore. However, there are not many clinical trials with positive results. Adlumiz (Anamorelin) is one of the more outstanding results.

Anamorelin (Adlumiz) will be launched in Japan in April 2021

Adlumiz (Anamorelin) Anamorelin is a new oral drug. Launched in Japan by Ono Pharmaceutical on April 21, 2021, it is the first drug to treat cancer cachexia. Launched this time is [エドルミズ® Tablets 50mg] Adlumiz (Anamorelin) 50mg tablets, which are used to treat CC in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignant tumors.

Anamorelin (Adlumiz) Actions and Benefits

Adlumiz is a selective ghrelin receptor agonist. Ghrelin is an endogenous peptide mainly secreted by the stomach. After binding to receptors, it can stimulate multiple pathways to positively regulate body weight, muscle mass, appetite and metabolism. Anamorelin can improve weight loss and loss of appetite in patients with cancer cachexia.

Adlumiz was approved in Japan in January 2021, mainly based on two multi-center double-blind randomized controlled studies, conducted in patients with non-small cell lung cancer (ONO-7643-04 study) and patients with colorectal cancer, gastric cancer, and pancreatic cancer (ONO-7643-05 study). Research results show that Adlumiz can significantly promote patients' appetite, increase patient weight, and muscle mass in CC caused by non-small cell lung cancer, colorectal cancer, gastric cancer, and pancreatic cancer. Compared with placebo, Anamorelin treatment of CC can significantly improve the patient's weight and hand grip strength, and also significantly improve the overall body weight and average score of the Anorexia and Cache Scale.

The launch of Adlumiz will improve the quality of life of all cancer cachexia patients

The launch of this drug in Japan will provide new treatment options for patients with cancer cachexia who have previously had no treatment. As cancer cachexia remains largely untreatable, the launch of Adlumiz, the first drug to treat cancer cachexia, marks an important milestone in improving the quality of life of all patients with cancer cachexia. According to the licensing agreement signed with Helsinn Healthcare SA, a company of the Swiss Helsinn Group, Ono Pharmaceutical has the exclusive rights to develop and commercialize Anamorelin in Japan, South Korea, and Taiwan, China.

Attached: Anamorelin Adlumiz (Anamorelin) indications

It is used to treat cancer cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignant tumors. 1. It should be used in patients with unresectable cancerous liquid non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. 2. Used for patients with cancer cachexia who have insufficient effects of nutritional therapy. 3. Used for patients who have more than 5% weight loss and loss of appetite within 6 months, and have more than 2 of the following (1) and (3). (1) Fatigue or feeling of fatigue. (2) Decreased muscle strength throughout the body. (3) Any one of the CRP value exceeds 0.5mg/dL, the hemoglobin value is less than 12g/dL, or the albumin value is less than 3.2g/dL.

Anamorelin Adlumiz (Anamorelin) Contraindications:

1. Patients with a history of allergies to the ingredients of this medicine. 2. Patients with congestive heart failure. 3. Patients with myocardial infarction or angina pectoris. 4. Patients with highly stimulating conduction system disorders (complete atrioventricular block, etc.). 5. Patients who are taking the next drug: clarithromycin, innavir, itraconazole, nelfonavir, Morinda officinalis, briconazole, ritonavir-containing preparations, and Comvita-containing special preparations. 6. Patients with moderate or above liver dysfunction (Child-Pugh classification b and c). 7. Patients who have difficulty in taking food orally due to organic abnormalities of the digestive tract such as digestive tract occlusion.

Note: Copyright statement, the copyright of all text, pictures and video materials on this website with the source "Medical Companion Travel" indicated belongs to the Medical Companion Travel website. Without authorization, any media, website or individual may not reproduce it, otherwise they will be held legally responsible. When obtaining written authorization for reprinting, the source "Medical Companion Travel" must be indicated. The purpose of reprinting articles on this website is to transmit information, and the reprinted content does not represent the position of this website. If it is involved, please contact our website for deletion.